Non-Hodgkin Lymphoma

Updated NCCN Guidelines recommend pemivibart in immunocompromised patients with B-cell lymphomas who are at higher risk of contracting COVID-19.

FDA’s ODAC voted on therapeutic approaches in lymphoma, bladder, prostate, and myeloma, and more from OncLive this week.

Pola-R-CHP demonstrated clinically meaningful PFS and safety in older patients with previously untreated diffuse large B-cell lymphoma.

Tafasitamab plus lenalidomide has received NMPA approval for patients with relapsed/refractory DLBCL who are ineligible for ASCT.

Lorenzo Falchi, MD, discusses the safety and pharmacodynamics of fixed-duration epcoritamab plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma

Lymphodepletion was associated with enhanced MAR T-cell response and antitumor activity with MT-601 in patients with relapsed/refractory lymphoma.

The FDA’s ODAC voted against the applicability of STARGLO trial results to U.S. patients with relapsed/refractory DLBCL.

Vivek G. Patel, MD, discusses the safety profile of bispecific antibodies for the treatment of patients with follicular lymphoma.

Lorenzo Falchi, MD, discusses the safety and efficacy of fixed-duration epcoritamab plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma.

Longer-term phase 1/2 data with AB-101 plus rituximab showed high, durable responses in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

OncLive announces the inductees of the 13th annual Giants of Cancer Care recognition program.

The FDA issues a CRL to a glioma imaging agent, an sBLA seeking approval of an epcoritamab triplet in follicular lymphoma is planned for submission, and more.

Vivek G Patel, MD, discusses the comparative efficacy and safety profiles of mosunetuzumab and epcoritamab in follicular lymphoma.

An sBLA seeking the approval of epcoritamab plus rituximab and lenalidomide for relapsed/refractory FL is planned to be submitted to the FDA.

The top 5 OncLive videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, multiple myeloma, and large B-cell lymphoma.

Response-adapted treatment with nivolumab with or without rituximab produced responses in treatment-naive follicular lymphoma.

The EC approved glofitamab with gemcitabine/oxaliplatin for patients with relapsed or refractory diffuse large B-cell lymphoma, ineligible for ASCT.

Educating patients and health care providers about BiTE-associated CRS and ICANS increases comfort levels with giving these agents in outpatient settings.

Sairah Ahmed, MD, explains the rationale for evaluating NTKR-255 after CAR T-cell therapy in relapsed/refractory large B-cell lymphoma.

Nirav Shah, MD, discusses the clinical implications and future directions for zamto-cel in patients with relapsed/refractory diffuse large B-cell lymphoma.

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, ovarian cancer, prostate cancer, breast cancer, and follicular lymphoma.

OncologyLive was onsite at the 2024 ASH Annual Meeting to film a Peer Exchange featuring expert commentary on follicular lymphoma.

Real-world data with axi-cel, tisa-cel, and brexu-cel in patients with B-cell malignancies proved comparable to other experiences with cellular therapy.

Julie M. Vose, MD, MBA, discusses the optimal use of epcoritamab for select patients with relapsed/refractory large B-cell lymphoma.

Axi-cel led to higher response rates but increased toxicity vs tisa-cel in older patients with relapsed/refractory DLBCL.